Last reviewed · How we verify
SU5416
At a glance
| Generic name | SU5416 |
|---|---|
| Sponsor | SUGEN |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy (PHASE1, PHASE2)
- SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma (PHASE2)
- Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer (PHASE3)
- SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors (PHASE1)
- SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy (PHASE2)
- SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer (PHASE1)
- SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma (PHASE2)
- SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SU5416 CI brief — competitive landscape report
- SU5416 updates RSS · CI watch RSS
- SUGEN portfolio CI